tracking
Featured Video
Thumbnail
The FDA has approved a second PCSK9 inhibitor, Repatha. Max Gomez, PhD, explains the drug's mechanism of action for lowering LDL cholesterol. PCSK9 inhibitors are approved for patients with a genetic type of high cholesterol, patients who cannot control their cholesterol with other treatments, or patients who cannot tolerate statins.
Editor's Picks
Recently Posted | Pages: 1 2 3
Most Viewed This Week
Most Viewed This Week | Pages: 1